HIDALGO OTTOLENGHI, JOSÉ RICARDO

Preferred name
HIDALGO OTTOLENGHI, JOSÉ RICARDO
Main Affiliation
ORCID
0000-0002-0708-8178
Scopus Author ID
56246158500

Settings

Now showing 1 - 10 of 14
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Growth references for weight, height, and body mass index for Ecuadorian children and adolescents aged 5-19 years
    (Sociedad Argentina de Pediatria, 2020-02-01)
    Wilmer Tarupi
    ;
    Yvan Lepage
    ;
    FELIX SALAZAR, MARIA LUISA  
    ;
    Claude Monnier
    ;
    Roland Hauspie
    Scopus© Citations 5
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    El papel de las revisiones sistemáticas. Comentarios
    (Ovid Technologies (Wolters Kluwer Health), 2011-11)
    HIDALGO OTTOLENGHI, JOSE RICARDO  
    Scopus© Citations 1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Leukodepleted Packed Red Blood Cells Transfusion in Patients Undergoing Major Cardiovascular Surgical Procedure: Systematic Review and Meta-Analysis
    (Hindawi Limited, 2019-02-25)
    SIMANCAS RACINES, DANIEL ALEJANDRO  
    ;
    Ingrid Arevalo-Rodriguez
    ;
    Gerard Urrutia
    ;
    Diana Buitrago-Garcia
    ;
    Solange Núñez-González
    <jats:p><jats:italic>Background</jats:italic>. Leukocytes contained in the allogeneic packed red blood cell (PRBC) are the cause of certain adverse reactions associated with blood transfusion. Leukoreduction consists of eliminating leukocytes in all blood products below the established safety levels for any patient type. In this systematic review, we appraise the clinical effectiveness of allogeneic leukodepleted (LD) PRBC transfusion for preventing infections and death in patients undergoing major cardiovascular surgical procedures.<jats:italic>Methods</jats:italic>. We searched randomized controlled trials (RCT), enrolling patients undergoing a major cardiovascular surgical procedure and transfused with LD-PRBC. Data were extracted, and risk of bias was assessed according to Cochrane guidelines. In addition, trial sequential analysis (TSA) was used to assess the need of conducting additional trials. Quality of the evidence was assessed using the GRADE approach.<jats:italic>Results</jats:italic>. Seven studies met the eligibility criteria. Quality of the evidence was rated as moderate for both outcomes. The risk ratio for death from any cause comparing the LD-PRBC versus non-LD-PRBC group was 0.69 (CI 95% = 0.53 to 0.90;<jats:italic>I</jats:italic><jats:sup>2</jats:sup> = 0%). The risk ratio for infection in the same comparison groups was 0.77 (CI 95% = 0.66 to 0.91;<jats:italic>I</jats:italic><jats:sup>2</jats:sup> = 0%). TSA showed a conclusive result in this outcome.<jats:italic>Conclusions</jats:italic>. We found evidence that supports the routine use of leukodepletion in patients undergoing a major cardiovascular surgical procedure requiring PRBC transfusion to prevent death and infection. In the case of infection, the evidence should be considered sufficient and conclusive and hence indicated that further trials would not be required.</jats:p>
    Scopus© Citations 21
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Imatinib for treating patients with chronic myelogeneous leukemia
    (Wiley, 2015-10-30)
    Vinicio Navas
    ;
    SIMANCAS RACINES, DANIEL ALEJANDRO  
    ;
    Andrés Felipe Cardona
    ;
    HIDALGO OTTOLENGHI, JOSE RICARDO  
    ;
    Luis Ernesto González
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Unlocking the potential: very-low-energy ketogenic therapy in obesity-related disorders
    (Informa UK Limited, 2025-01-16)
    Daniel Simancas-Racines
    ;
    Claudia Reytor-González
    ;
    ZAMBRANO ESPINOSA, ANA KARINA  
    ;
    Giuseppe Annunziata
    ;
    Angelo Michele Carella
    The Very Low-Energy Ketogenic Therapy (VLEKT) is a structured, multi-phase dietary regimen characterized by a carbohydrate intake of less than 50 g/day and a daily caloric intake of fewer than 800 kcal, which induces ketosis and facilitates significant weight loss. Evidence suggests that this nutritional therapy can improve glycemic control, lipid profiles, and blood pressure, making it a promising option for managing type 2 diabetes (T2D) and reducing cardiovascular risk. These benefits are achieved through reductions in triglycerides and low-density lipoprotein cholesterol (LDL-c), alongside increases in high-density lipoprotein cholesterol (HDL-c). However, the effects of the VLEKT on lipid metabolism remain controversial. The review emphasizes the urgent need for further research to validate the long-term safety and efficacy of the VLEKT. It also highlights the critical role of personalized dietary plans, supervised by healthcare professionals, to optimize health outcomes and address individual patient needs.
    Scopus© Citations 12
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Scopus© Citations 6
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Identification of mutations on the EMD and EYA4 genes associated with Emery–Dreifuss muscular dystrophy and deafness: a case report
    (Frontiers Media SA, 2023-05-12)
    ZAMBRANO ESPINOSA, ANA KARINA  
    ;
    Rita Ibarra-Castillo
    ;
    PAZ CRUZ, ELUIS ANDRES  
    ;
    CADENA ULLAURI, SANTIAGO ANDRE  
    ;
    José Luis Laso-Bayas
    <jats:sec><jats:title>Introduction</jats:title><jats:p>Hearing loss is the most common sensory disability, and it is estimated that 50% of cases are caused by genetic factors. One of the genes associated with deafness is the eyes absent homolog 4 (<jats:italic>EYA4</jats:italic>) gene, a transcription factor related to the development and function of the inner ear. Emery–Dreifuss muscular dystrophy is a rare inherited disease characterized by atrophy and weakness of the humeroperoneal muscles, multi-joint contractures, and cardiac manifestations. It is inherited in an autosomal-dominant, X-linked, or less frequently autosomal recessive manner; one of the genes associated with EDMD is the emerin (<jats:italic>EMD)</jats:italic> gene.</jats:p></jats:sec><jats:sec><jats:title>Case description</jats:title><jats:p>A total of two Ecuadorian siblings aged 57 (Subject A) and 55 (Subject B) were diagnosed with deafness and an unspecified type of muscular dystrophy based on family history and clinical findings. Next-generation sequencing (NGS) using the TruSight Cardio and Inherited Disease kits at the Centro de Investigación Genética y Genómica CIGG, Universidad UTE, was performed. The genetic analyses showed two mutations: a stop mutation in exon 11/20 (NM_004100.4:c.940G&amp;gt;T) of the <jats:italic>EYA4</jats:italic> gene and a missense mutation in exon 6 (NM_000117.2:c.548C&amp;gt;G) of the <jats:italic>EMD</jats:italic> gene.</jats:p></jats:sec><jats:sec><jats:title>Discussion and conclusion</jats:title><jats:p>The <jats:italic>in silico</jats:italic> predictions described the <jats:italic>EYA4</jats:italic> variant as likely pathogenic and the <jats:italic>EMD</jats:italic> variant as a variant of uncertain significance (VUS). Moreover, an ancestry analysis was performed using 46 Ancestry Informative Insertion/Deletion Markers (AIM-InDels), and the ancestral composition of subject A was 46% African, 26.1% European, and 27.9% American Indian ancestry, whereas the ancestral composition of subject B was 41.3% African, 38.2% European, and 20.5% American Indian ancestry. The present case report describes two Ecuadorian siblings with a mainly African ancestral component, muscular dystrophy, and deafness phenotypes. Moreover, using next-generation sequencing (NGS), a mutation in the <jats:italic>EMD</jats:italic> and a novel mutation in <jats:italic>EYA4</jats:italic> genes possibly associated with the subjects' phenotype were identified and discussed.</jats:p></jats:sec>
    Scopus© Citations 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Exercise training for adult lung transplant recipients
    (Wiley, 2021-07-20)
    Ruvistay Gutierrez-Arias
    ;
    Maria José Martinez-Zapata
    ;
    Monica C Gaete-Mahn
    ;
    Dimelza Osorio
    ;
    Luis Bustos
    Scopus© Citations 16
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Identification of biomedical journals in Spain and Latin America
    (Wiley, 2015-07-20)
    Xavier Bonfill
    ;
    Dimelza Osorio
    ;
    Margarita Posso
    ;
    Ivan Solà
    ;
    Gabriel Rada
    <jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>Journals in languages other than English that publish original clinical research are often not well covered in the main biomedical databases and therefore often not included in systematic reviews. This study aimed to identify Spanish language biomedical journals from Spain and Latin America and to describe their main features.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Journals were identified in electronic databases, publishers' catalogues and local registries. Eligibility was determined by assessing data from these sources or the journals' websites, when available.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>A total of 2457 journals were initially identified; 1498 met inclusion criteria. Spain (27.3%), Mexico (16.0%), Argentina (15.1%) and Chile (11.9%) had the highest number of journals. Most (85.8%) are currently active; 87.8% have an <jats:styled-content style="fixed-case">ISSN</jats:styled-content>. The median and mean length of publication were 22 and 29 years, respectively. A total of 66.0% were indexed in at least one database; 3.0% had an impact factor in 2012. A total of 845 journals had websites (56.4%), of which 700 (82.8%) were searchable and 681 (80.6%) free of charge.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Most of the identified journals have no impact factor or are not indexed in any of the major databases. The list of identified biomedical journals can be a useful resource when conducting hand searching activities and identifying clinical trials that otherwise would not be retrieved.</jats:p></jats:sec>
    Scopus© Citations 16
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Weighty matters: Unraveling the impact of obesity on colorectal cancer and nutritional interventions
    (Elsevier BV, 2025-09-01)
    SIMANCAS RACINES, DANIEL ALEJANDRO
    ;
    REYTOR GONZÁLEZ, CLAUDIA MARÍA
    ;
    Evelyn Frias-Toral
    ;
    Christos S. Katsanos
    ;
    HIDALGO OTTOLENGHI, JOSE RICARDO  
    This narrative review explores the influence of obesity on colorectal cancer, focusing on obesity-related factors, including chronic inflammation, metabolic dysregulation, and gut microbiota imbalance, which collectively create a pro-carcinogenic environment that increases colorectal cancer risk and complicates treatment outcomes. The findings indicate that obesity not only accelerates tumor progression but also presents challenges in colorectal cancer treatment, such as higher rates of surgical complications due to excess adipose tissue and altered pharmacokinetics that can reduce chemotherapy efficacy. Nutritional and lifestyle interventions, particularly weight management and anti-inflammatory nutritional therapies, are highlighted as effective strategies to reduce colorectal cancer risk and support treatment in patients with obesity. The study emphasizes the importance of personalized colorectal cancer treatment approaches for individuals with obesity and calls for public health policies targeting obesity prevention, which could significantly decrease colorectal cancer incidence and healthcare burdens associated with this high-risk population.
    Scopus© Citations 16